Results 1 to 10 of about 16,510 (126)

Comparative real-world study of apalutamide and darolutamide in Japanese patients with non-metastatic castration-resistant prostate cancer [PDF]

BMC Urology
Background Non-metastatic castration-resistant prostate cancer (nmCRPC) is often asymptomatic but carries a risk of progression to metastatic disease.
Maiko Ikeda, Koichi Uemura, Yusuke Ito, Hiroki Ito, Takashi Kawahara, Hisashi Hasumi, Jun-Ichi Teranishi, Kazuhide Makiyama, Hiroji Uemura   +8 more
doaj   +2 more sources

Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study [PDF]

Acta Oncologica
Background: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated.
Charlotte Alverbratt, Fredrik Sandin, Viktor Kolmbäck, Hans Garmo, Ola Bratt, Ingela Franck Lissbrant   +5 more
doaj   +2 more sources

Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance [PDF]

Investigative and Clinical Urology, 2021
Purpose: To investigate germline and somatic mutation profiles in Korean patients with prostate cancer using liquid biopsy and solid tissue testing and to evaluate the prognostic value of circulating tumor DNA (ctDNA) in predicting castration resistance ...
Jiwoong Yu , Eunhae Cho , Joongwon Choi , Joung Eun Lim , Junnam Lee , Minyong Kang, Hyun Hwan Sung , Byong Chang Jeong , Seong Il Seo , Seong Soo Jeon , Hyun Moo Lee , Hwang Gyun Jeon   +11 more
doaj   +1 more source

Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy [PDF]

Journal of Urologic Oncology, 2023
Purpose In present, the use of androgen receptor targeting agents (ARTA) is one of the standard treatments for metastatic castration-resistant prostate cancer (mCRPC) without previous chemotherapy.
Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, Doo Yong Chung   +3 more
doaj   +1 more source

Bioinformatic Analysis of Potential Key Genes in Castration-resistant Prostate Cancer Development [PDF]

Zhongguo quanke yixue, 2022
BackgroundCastration-resistant prostate cancer (CRPC) is one of the most prevalent cancers in males with a high fatality rate. Its molecular mechanism is still unclear, and there is no effective treatment.ObjectiveTo explore the key genes involved in ...
DONG Jingting, HENG Li, KANG Shaosan, LIU Jian, TIAN Zhichong, ZHANG Liguo, ZHANG Jincun, LI Zhiguo, SHEN Hong, CAO Fenghong
doaj   +1 more source

Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities [PDF]

International Brazilian Journal of Urology, 2021
Background: Non-metastatic castration resistant prostate cancer (M0 CRPC) has seen important developments in drugs and diagnostic tools in the last two years.
Fernando Maluf, Andrey Soares, Guilherme Avanço, Aline Lury Hada, Ana Paula Garcia Cardoso, Arie Carneiro, Daniel Herchenhorn, Denis Leonardo Fontes Jardim, Fabio Augusto Schutz, Fabio Roberto Kater, Felipe Moraes Toledo Pereira, Fernando Sabino Marques Monteiro, Igor Alexandre Protzner Morbeck, João Francisco Navarro Reolon, Karine Martins da Trindade, Livia Maria Querino da Silvo Andrade, Lucas Mendes Nogueira, Renato Furoni, Ricardo Azze Natel, Rodolfo Borges dos Reis, Rodrigo Nogueira Fogace, Vinicius Carrera Souza   +21 more
doaj   +1 more source

Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved]

NIHR Open Research, 2023
Background: Prostate cancer is the most commonly diagnosed malignancy in the UK. Castrate resistant prostate cancer (CRPC) can be difficult to manage with response to next generation hormonal treatment variable.
Rebecca Maier, Aislinn Cooper, Robert Chandler, John Marshall, Simon Crabb, Amit Bahl, Ian Pedley, Suneil Jain, John Staffurth, Rob Jones, Rakesh Heer, Paul Gravestock, Miranda Morton, Emma Clark, Holly Fisher, Shirya Sharma, Ruth Wood, Jenn Walker, Nichola Waugh, Helen Hancock   +19 more
doaj   +1 more source

Molecular Mechanism of Oxidative Stress Mediated Androgen Receptor Signal Reactivation in Prostatic Cancer Progression [PDF]

Zhongguo quanke yixue, 2022
After androgen-deprivation therapy, a large amount of reactive oxygen species are produced in patients with advanced prostate cancer (PCa) to aggravate oxidative stress.
HENG Li, ZHANG Liguo, DONG Jingting, LI Zhiguo, CAO Fenghong
doaj   +1 more source

Metastatic Castration-Resistant Prostate Cancer in Brazil: a Real-World Investigation Using INCA Database

Revista Brasileira de Cancerologia, 2023
Introduction: Prostate cancer is the second most common cancer in men worldwide. In Brazil, regional disparities in incidences of intermediate and high-risk in late-diagnosed PC cases are expected.
Lorena Pozzo, Mércia Liane de Oliveira, Lucilena Rebelo Monteiro, Mario Olímpio de Menezes, Francesco Giammarile, Marcus Vinícius Sadi   +5 more
doaj   +1 more source

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

BMC Urology, 2020
Background Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles.
Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Erica Horodniceanu, A. Reginald Waldeck, Stacey J Simmons   +8 more
doaj   +1 more source